Renovatio clinical

1. Incyte Corporation $3,098,234 439 payments
2. Merck Sharp & Dohme Corporation $2,361,793 125 payments
3. Vertex Pharmaceuticals Incorporated $1,688,293 15 payments
4. Genentech, Inc. $783,713 40 payments
5. Janssen Research & Development, LLC $455,130 6 payments
6. Radius Health, Inc. $267,466 2 payments
7. Seattle Genetics, Inc. $265,684 19 payments
8. Amgen Inc. $189,295 1 payment
9. AbbVie, Inc. $152,925 35 payments
10. Karyopharm Therapeutics Inc. $39,245 5 payments

1. A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer $1,035,583 26 payments
2. A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain $946,539 3 payments
3. A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer NSCLC $573,669 30 payments
4. A Phase 2, Open-label Study Evaluating Efficacy and Safety of VX-864 in Subjects With Alpha-1 Antitrypsin Deficiency Who Have the PiZZ Genotype, Over 48 Weeks $490,124 3 payments
5. A Phase 1B Evaluating Safety, Efficacy, PK and PD of Glofitamab Plus Gem-Ox in Rem Ptswith R/R Dlbcl $409,852 22 payments
6. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma $320,008 3 payments
7. A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib $294,467 12 payments
8. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3K Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis $292,416 1 payment
9. A Randomized, Multicenter, Phase 2 Study Of Elacestrant (rad1901) Versus Investigators Choice Of Fulvestrant Or Aromatase Inhibitor Therapy For The Treatment Of Postmenopausal Women With Er+/her2- Breast Cancer $267,466 2 payments
10. A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) $265,140 39 payments

1. Patient care $150 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.